Oxford Biomedica plc
OXB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -6.1% | 53.5% | 9.3% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 43.2% | 44.5% | 35.3% | 38.3% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -33% | -12.1% | -63.5% | -283% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | £0 | £0 | £0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -36% | -13.7% | -63.9% | -235.7% |
| EPS | -0.25 | -0.1 | -0.31 | -1.13 |
| % Growth | -150% | 67.7% | 72.6% | – |
| EPS Diluted | -0.25 | -0.1 | -0.31 | -1.13 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | £0 | -£0 | -£0 |
| % Margin | -8.3% | 6.4% | -38.7% | -241.5% |